Devrim Aran has extensive experience in pharmaceutical/biotech company management currently leading R&D, regulatory, and global business strategy of small molecules in complex chronic diseases at Innox Corp as Global CEO and GPL (Global Project Leader). Previously, Devrim Aran was the CEO of Arkhe Pharmaceuticals Corp where he led R&D, manufacture and global business strategy of biologics, biosimilars, novel inhalation products and injectable generics. Devrim Aran was the Head of US Commercialization for top onc/hem products at Novartis with more than $ 1 Billion in revenue. He was also a member of Novartis GDP (Global Development Project) team in IDTI (Infectious Disease, Transplant and Immunology) business unit. Prior to that, Devrim Aran was the Head of Business Solutions at Abraxis Oncology/APP where he was responsible for pricing, contracting, reimbursement, account management and commercialization of Abraxane (nabpaclitaxel) in solid tumors and ultimately drove $ 135 M net sales in 9 months at launch with the help of pricing and contracting strategies. Devrim Aran was the Head of Marketing at Roche Laboratories where he was ultimately responsible for the turnaround of Kytril (granisetron) in CINV/RINV (chemo and radiation induced nausea and vomiting) and the launch in PONV (postoperative nausea and vomiting).